- Home
- GRRR vs GANX Comparison
GRRR vs GANX Comparison
Compare GRRR & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRRR
- GANX
- Stock Information
- Founded
- GRRR 2001
- GANX 2017
- Country
- GRRR United Kingdom
- GANX United States
- Employees
- GRRR N/A
- GANX N/A
- Industry
- GRRR Computer Software: Prepackaged Software
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- GRRR Technology
- GANX Health Care
- Exchange
- GRRR Nasdaq
- GANX Nasdaq
- Market Cap
- GRRR 47.8M
- GANX 41.9M
- IPO Year
- GRRR N/A
- GANX 2021
- Fundamental
- Price
- GRRR $4.35
- GANX $1.62
- Analyst Decision
- GRRR Buy
- GANX Strong Buy
- Analyst Count
- GRRR 1
- GANX 4
- Target Price
- GRRR $9.00
- GANX $7.75
- AVG Volume (30 Days)
- GRRR 415.2K
- GANX 281.8K
- Earning Date
- GRRR 11-29-2024
- GANX 11-14-2024
- Dividend Yield
- GRRR N/A
- GANX N/A
- EPS Growth
- GRRR N/A
- GANX N/A
- EPS
- GRRR 2.28
- GANX N/A
- Revenue
- GRRR $78,940,347.00
- GANX N/A
- Revenue This Year
- GRRR $15.59
- GANX N/A
- Revenue Next Year
- GRRR $20.59
- GANX $300.03
- P/E Ratio
- GRRR $1.91
- GANX N/A
- Revenue Growth
- GRRR 424.97
- GANX N/A
- 52 Week Low
- GRRR $2.09
- GANX $0.89
- 52 Week High
- GRRR $13.00
- GANX $5.33
- Technical
- Relative Strength Index (RSI)
- GRRR 52.57
- GANX 35.06
- Support Level
- GRRR $3.71
- GANX $1.63
- Resistance Level
- GRRR $4.79
- GANX $2.00
- Average True Range (ATR)
- GRRR 0.31
- GANX 0.22
- MACD
- GRRR -0.05
- GANX -0.08
- Stochastic Oscillator
- GRRR 59.26
- GANX 7.23
About GRRR Gorilla Technology Group Inc. Ordinary shares
Gorilla Technology Group Inc is primarily engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.